Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Avience Biomedicals Ltd (AVIENCE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: AVIENCE Medical Equipment/Supplies/Accessories | Small Cap | Avience Biomedicals Share Price
BSE Share Price
Not Listed
Not Listed
Avience Biomedicals Ltd (AVIENCE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: AVIENCE Medical Equipment/Supplies/Accessories | Small Cap | Avience Biomedicals Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹194 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹16
TTM Sales
₹52.5 Cr.
Book Value per Share
₹44.2
P/E Ratio
22.21
In line with its 5-year historical median
Industry PE
129.2
Price to Book (P/B)
8.02
Higher than its 5-year historical median
Price to Sales (P/S)
3.70
Lower than its 5-year historical median
EV/EBITDA
13.90
In line with its 5-year historical median
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
49.90%
Outperforms industry median
Return on Capital Employed (ROCE)
34.16%
Outperforms industry median
Return on Assets (ROA)
15.90%
Operating Profit Margin
25.5%
Net Profit Margin
15.99%
Gross Profit Margin
23.6%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
77.68%
Operating Profit Growth (1 Year)
-
179.27%
Net Profit Growth (1 Year)
-
237.85%
Asset Quality
Promoter Holding
64.59%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹19 Cr.
Equity
₹5.5 Cr.
Face Value
₹10
All Time Low / High
₹0.00 / 0.00
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Strong
Is Avience Biomedicals Ltd a good quality company?
Avience Biomedicals Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Avience Biomedicals Ltd performance compare with that of its Peers?
Revenue growth of Avience Biomedicals Ltd vs industry peers?
Avience Biomedicals Ltd revenue CAGR is %, compared to the industry median CAGR of 19.27%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Avience Biomedicals Ltd?
Promoters hold 64.59% of the Avience Biomedicals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Avience Biomedicals Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Avience Biomedicals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 21.4% | 20.6% | 30.4% | 31.6% | - |
| Value Creation Index ⓘ | 0.5 | 0.5 | 1.2 | 1.3 | - |
Growth Parameters ⓘ |
|||||
| Sales ⓘ | 10.2 | 10.9 | 16.3 | 28.9 | 35 |
| Sales YoY Gr. | - | 7.6% | 48.9% | 77.7% | - |
| Adj EPS ⓘ | 2.7 | 2.2 | 6 | 12.6 | 12.3 |
| YoY Gr. | - | -18.8% | 173.2% | 109.8% | - |
| BVPS (₹) ⓘ | 10.6 | 12.4 | 18.4 | 50.9 | 40.1 |
| Adj Net Profit ⓘ | 0.7 | 0.7 | 2 | 5.1 | 7 |
| Cash Flow from Ops. ⓘ | -2 | 1.6 | 0.2 | 3.2 | - |
| Debt/CF from Ops. ⓘ | -1.3 | 1.7 | 33.4 | 4.3 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 41.7% | 77.7% | ||||
| Adj EPS ⓘ | NA | NA | 67% | 109.8% | ||||
| BVPSⓘ | NA | NA | 68.9% | 176.2% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 25.7 | 21.1 | 39 | 38.3 | 27 |
| Op. Profit Mgn % ⓘ | 12 | 13.3 | 19.5 | 26.6 | NAN |
| Net Profit Mgn % ⓘ | 7.1 | 6.6 | 12.1 | 17.6 | 19.1 |
| Debt to Equity ⓘ | 0.9 | 0.7 | 1.3 | 0.7 | - |
| Working Cap Days ⓘ | 0 | 203 | 226 | 205 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 132 | 114 | 90 | 0 |
Valuation of Avience Biomedicals - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'24 | Mar'25 |
|---|---|---|
| Sales | 24 | 45 |
| Operating Expenses ⓘ + | 20 | 34 |
| Operating Profit ⓘ | 4 | 11 |
| Operating Profit Margin (%) | 17.1% | 25.3% |
| Other Income ⓘ + | 0 | 1 |
| Interest ⓘ | 1 | 2 |
| Depreciation ⓘ | 1 | 1 |
| Profit Before Tax ⓘ | 3 | 10 |
| Tax ⓘ | 1 | 3 |
| Profit After Tax | 2 | 7 |
| PAT Margin (%) | 8.9% | 16.0% |
| Adjusted EPS (₹) | 6.5 | 17.9 |
| Dividend Payout Ratio (%) | 0% | 0% |
| PARTICULARS | Mar'24 | Mar'25 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 6 | 23 | |||||||||
| Debt + | 14 | 21 | |||||||||
| Minority Interest | 0 | 0 | |||||||||
| Trade Payables | 6 | 7 | |||||||||
| Others Liabilities ⓘ | 9 | 5 | |||||||||
| Total Liabilities ⓘ | 35 | 56 | |||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 10 | 13 | |||||||||
| CWIP ⓘ | 0 | 5 | |||||||||
| Investments ⓘ | 0 | 0 | |||||||||
| Inventories | 12 | 13 | |||||||||
| Trade Receivables | 8 | 17 | |||||||||
| Cash Equivalents | 0 | 5 | |||||||||
| Others Assets ⓘ | 3 | 3 | |||||||||
| Total Assets ⓘ | 35 | 56 | |||||||||
| PARTICULARS | Mar'24 | Mar'25 |
|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 1 | 4 |
| Cash Flow From Investing Activity ⓘ + | -4 | -9 |
| Cash Flow From Financing Activity ⓘ + | 3 | 9 |
| Net Cash Flow ⓘ | -0 | 4 |
| PARTICULARS | Mar'24 | Mar'25 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 34.47 | 49.9 | ||||||||
| ROCE (%) | 18.25 | 34.16 | ||||||||
| Asset Turnover Ratio | 0.69 | 0.99 | ||||||||
| PAT to CFO Conversion(x) | 0.5 | 0.57 | ||||||||
| Working Capital Days | ||||||||||
| Receivable Days | 123.20 | 102.10 | ||||||||
| Inventory Days | 188.80 | 102.70 | ||||||||
| Payable Days | 129.90 | 86.40 | ||||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Avience Biomedicals Ltd FAQs
The current trading price of Avience Biomedicals on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Avience Biomedicals stood at ₹194.4 Cr
The latest P/E ratio of Avience Biomedicals as of 31-Dec-1969 is 28.88.
The latest P/B ratio of Avience Biomedicals as of 31-Dec-1969 is 8.85.
The 52-week high of Avience Biomedicals is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Avience Biomedicals is ₹35.31 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Avience Biomedicals Ltd is a below average quality company.
The key valuation ratios of Avience Biomedicals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Avience Biomedicals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Avience Biomedicals Ltd
Avience Biomedicals was incorporated as Avience Biomedicals Private Limited in December 23, 2019, in Delhi. Subsequently, the company was converted into a Public Limited Company pursuant to shareholders resolution passed at the Extra Ordinary General Meeting of the company held on June 26, 2024 and the name of the company was changed from ‘Avience Biomedicals Private Limited’ to ‘Avience Biomedicals Limited’ on September 03,2024.
The company is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) products and medical devices. The company commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM), Covid, Human Immunodeficiency Viruses (HIV), HBs AG, Malaria, Dengue and others aimed at aiding medical institutions with affordable and good-quality solutions. The company has expanded its product range from IVD rapid test kits to include a comprehensive line of medical devices such as Serology products, Biochemistry Analyser and Biochemistry Reagents, showcasing a dedication to addressing various healthcare needs.
Being majorly into B2B and B2C market, its products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing, the company also act as distributors and traders of medical equipment. The company is an ISO 9001:2016, ISO 13485, ZED MSME Gold and Good Manufacturing Practice (GMP) certified organization.
Business area of the company
The company is primarily engaged in the business of manufacturing and selling of medical consumables. Its diversified product portfolio can primarily be divided into two main categories -- Manufacturing of Medical Consumables and Distribution of branded equipment.
Products of the company
Reagents & Consumable
- Biochemistry Reagents - for liver function tests (LFT), kidney function tests (KFT), lipid profiles, glucose tests, etc.
- Haematology Reagents - for complete blood count (CBC), differential count, etc.
- Immunoassay Reagents - for detecting hormones, infectious diseases, and tumour markers.
- Consumables - cuvettes, pipette tips, test tubes, microplates, and filters.
Diagnostic Instruments & Equipment
- Automated Biochemistry Analysers - fully or semi-automated systems.
- Haematology Analysers - 3-part or 5-part differential systems.
- Immunoassay Analysers - CLIA systems, ELISA readers and washers.
- Molecular Diagnostic Instruments - PCR machines, thermocyclers.
- Microbiology Instruments - incubators, autoclaves, colony counters.
- Electrolyte Analyser - used to measure the concentration of electrolytes in biological fluids such as blood, serum, plasma, or urine.
History and milestones
- 2020-21: Inauguration of Noida Factory.
- 2020-21: Initiated E-Commerce Sales through Government e-Marketplace (GeM) OEM.
- 2021-22: Tenfold increase in turnover during FY 2021-22.
- 2021-22: The company obtained 4 manufacturing licenses.
- 2022-23: The company received approval for 10 additional production licenses.
- 2023-24: The company secured an allotment of commercial land measuring 2,100 square meters within the Medical Device Park, located in the Yamuna Expressway Industrial Development Area, at a nominal lease rate.
- 2023-24: The company dispatched first export order.
- 2023-24: The company successfully completed first export order to Somalia and entered the African continent.
- 2023-24: The company received approval from the Ethiopian Food and Drug Authority (EFDA) to export its products.
- 2023-24: The company received a large government supply order after winning a bid in Andhra Pradesh for Rs 82.05 lakh.
- 2023-24: The WHO recognized the company’s manufacturing process as a Good Manufacturing Practice (GMP) for producing quality products that meet international quality standards.
- 2023-24: The company secured MSME ZED Gold Certification.
- 2023-24: The company received approval for 31 new production licenses.
- 2024-25: The company laid foundation stone for the new large production facility at the Medical Device Park at Yamuna Expressway Industrial Development Area.
- 2024-25: The company became one of the few manufacturers in India to receive validation for the sickle cell test from ICMR.
- 2024-25: The company obtained its first license for manufacturing hematology equipment in FY 2024-25.
- 2024-25: The company transitioned to a public company, marking a significant milestone in its growth and expansion.
- 2024-25: The company received approval for 32 new production licenses.
- 2025-26: The company received approval for 11 new production licenses.
- 2026-27: The company received approval for 10 new production licenses.
You have 43 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
